Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALK016
MIFTS: 44

Alk-Negative Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma 58
Anaplastic Large Cell Lymphoma, Alk-Negative 17 32
Anaplastic Large Cell Lymphoma, Alk Negative 71
Anaplastic Large Cell Lymphoma, Alk-Positive 71
Alk- Anaplastic Large Cell Lymphoma 58
Alk- Alcl 58

Characteristics:

Orphanet epidemiological data:

58
alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

ICD10 32 C84.7
ICD10 via Orphanet 33 C84.7
UMLS via Orphanet 72 C1332078
Orphanet 58 ORPHA300903
UMLS 71 C1332078 C1332079
Sources

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

About this section
MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk-negative, is related to alk-positive anaplastic large cell lymphoma and anaplastic large cell lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Prednisone and Pirarubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and nk cells, and related phenotypes are homeostasis/metabolism and growth/size/body region

Sources

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 33.3 STAT3 ALK
2 anaplastic large cell lymphoma 31.2 STAT3 CXCR3 CCR4 ALK
3 lymphoma, hodgkin, classic 31.0 CCR4 BCL2L1 BCL2 ALK
4 reticulosarcoma 30.4 MYC BCL2 ALK
5 breast implant-associated anaplastic large cell lymphoma 30.2 STAT3 DUSP22 ALK
6 peripheral t-cell lymphoma 29.8 STAT3 DUSP22 CXCR3 CD274 CCR4 ALK
7 lymphoma 29.5 STAT3 MYC CD274 BCL2L1 BCL2 BAX
8 cutaneous t cell lymphoma 29.2 STAT3 DPP4 CXCR3 CCR4 ADA
9 t-cell lymphoblastic leukemia/lymphoma 28.9 STAT3 MYC CCR4 BCL2L1 BCL2 ADA
10 b-cell lymphoma 28.6 STAT3 MYC CD274 BCL2L1 BCL2 BAX
11 myeloma, multiple 28.4 STAT3 PMAIP1 MYC CD274 BCL2L1 BCL2
12 adult t-cell leukemia 28.4 STAT3 PMAIP1 MYC CD274 CCR4 BCL2L1
13 lymphoma, non-hodgkin, familial 27.8 STAT3 PMAIP1 MYC DPP4 CD274 BCL2L1
14 indolent b-cell non-hodgkin lymphoma 10.4 BCL2L1 BAX
15 pleural lipoma 10.4 ALK ADA
16 kashin-beck disease 10.4 BCL2 BAX
17 thrombocytopenia 10.4
18 lymphomatoid papulosis 10.4
19 parkinson disease, mitochondrial 10.3 BCL2L1 BAX
20 primary mediastinal large b-cell lymphoma 10.3 CD274 BCL2
21 absolute glaucoma 10.3 BCL2L1 BCL2 BAX
22 focal cortical dysplasia, type ii 10.2 BCL2L1 BCL2 BAX
23 diffuse large b-cell lymphoma of the central nervous system 10.2 MYC BCL2
24 aplastic anemia 10.2
25 myelodysplastic syndrome 10.2
26 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
27 t-cell lymphoma, subcutaneous panniculitis-like 10.2
28 hemophagocytic lymphohistiocytosis 10.2
29 lymphoblastic lymphoma 10.2
30 sarcoma 10.2
31 respiratory failure 10.2
32 disseminated intravascular coagulation 10.2
33 alcoholic hepatitis 10.2
34 hepatitis a 10.2
35 capillary leak syndrome 10.2
36 alcohol use disorder 10.2
37 ichthyosis 10.2
38 squamous cell carcinoma 10.2
39 spindle cell sarcoma 10.2
40 t-cell adult acute lymphocytic leukemia 10.2
41 neuropathy 10.2
42 hypereosinophilic syndrome 10.2
43 47,xyy 10.2
44 granulomatous slack skin disease 10.2
45 ichthyosis, acquired 10.2
46 leukemia, t-cell, chronic 10.2
47 soft tissue sarcoma 10.2
48 t-cell non-hodgkin lymphoma 10.2
49 rapidly involuting congenital hemangioma 10.2
50 primary cutaneous anaplastic large cell lymphoma 10.2

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma
Sources

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.22 ADA ALK BAX BCL2 BCL2L1 CD274
2 growth/size/body region MP:0005378 10.2 ADA ADARB1 ALK BAX BCL2 BCL2L1
3 hematopoietic system MP:0005397 10.17 ADA BAX BCL2 BCL2L1 CCR4 CD274
4 immune system MP:0005387 10.15 ADA BAX BCL2 BCL2L1 CCR4 CD274
5 endocrine/exocrine gland MP:0005379 10.13 ADA ALK BAX BCL2 BCL2L1 DPP4
6 mortality/aging MP:0010768 10.13 ADA ADARB1 ALK BAX BCL2 BCL2L1
7 muscle MP:0005369 9.86 ADA ADARB1 BAX BCL2 MSC MYC
8 neoplasm MP:0002006 9.81 ALK BAX BCL2 BCL2L1 CXCR3 FRK
9 renal/urinary system MP:0005367 9.5 ADA BAX BCL2 CXCR3 DUSP22 STAT3
10 respiratory system MP:0005388 9.28 ADA ALK BAX CCR4 CXCR3 DPP4
Sources

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Pirarubicin Investigational Phase 4 72496-41-4
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
5
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
6 Antineoplastic Agents, Hormonal Phase 3
7 Hormones Phase 3
8 Hormone Antagonists Phase 3
9 Alkylating Agents Phase 3
10 Immunosuppressive Agents Phase 3
11 glucocorticoids Phase 3
12 Immunologic Factors Phase 3
13 Tubulin Modulators Phase 3
14 Antirheumatic Agents Phase 3
15 Antimitotic Agents Phase 3
16 Anti-Inflammatory Agents Phase 3
17
Liposomal doxorubicin Phase 3 31703
18 Anti-Bacterial Agents Phase 3
19 Antibiotics, Antitubercular Phase 3
20
Carmustine Approved, Investigational Phase 1, Phase 2 154-93-8 2578
21
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
22
Melphalan Approved Phase 1, Phase 2 148-82-3 460612 4053
23
alemtuzumab Approved, Investigational Phase 2 216503-57-0
24
nivolumab Approved Phase 2 946414-94-4
25
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
26
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
27
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
28 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
29
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
30
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
33
Cytarabine Approved, Experimental, Investigational Phase 2 147-94-4, 65-46-3 6253
34
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
37
leucovorin Approved Phase 2 58-05-9 6006 143
38
Ifosfamide Approved Phase 2 3778-73-2 3690
39
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
40
Ichthammol Approved Phase 2 8029-68-3
41
Phenylalanine Approved, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2 6140
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
44
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
45
Cortisone Experimental Phase 1, Phase 2 53-06-5 222786
46 Tin Fluorides Phase 2
47 Nitrogen Mustard Compounds Phase 1, Phase 2
48 Methylprednisolone Acetate Phase 1, Phase 2
49 Angiogenesis Inhibitors Phase 1, Phase 2
50 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
3 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Unknown status NCT02419287 Phase 2 crizotinib
4 A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;Vincristine;pralatrexate
5 Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma Completed NCT01035463 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Lenalidomide;Melphalan
6 Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL) Completed NCT01679860 Phase 2 Clin B (CHOP- CAMPATH) Chemo-immunotherapy
7 A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT03719898 Phase 2 Brigatinib
8 Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) Recruiting NCT03703050 Phase 2 Nivolumab cohort 1;Nivolumab cohort 2
9 A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3) Recruiting NCT03505554 Phase 2 Lorlatinib
10 A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL Recruiting NCT04423926 Phase 1, Phase 2 Lenalidomide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisolone
11 A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
12 A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy Active, not recruiting NCT02462538 Phase 1, Phase 2 Brentuximab vedotin;Imatinib
13 Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Active, not recruiting NCT02572453 Phase 2 Onalespib
14 A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) Suspended NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
15 An Open-Label, Phase 1/2 Dose Escalation and Expansion Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Brigatinib as Monotherapy in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors Withdrawn NCT04260009 Phase 1, Phase 2 Brigatinib;Brigatinib AAF
16 A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma Withdrawn NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
17 Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL) Completed NCT01366170
18 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma Recruiting NCT03603847

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Sources

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

About this section
Sources

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

40
T Cells, Breast, Nk Cells, Bone, Lymph Node, Lung, Myeloid
Sources

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 132)
# Title Authors PMID Year
1
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma. 61
32576784 2020
2
Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with RUNX3 overexpression. 61
32499905 2020
3
Breast Implant-associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms. 61
32302264 2020
4
Incidence of Anaplastic Large Cell Lymphoma and Breast-Implant-Associated Lymphoma-An Analysis of a Certified Tumor Registry over 17 Years. 61
32344893 2020
5
Endobronchial pseudocarcinomatous hyperplasia mimicking squamous cell carcinoma associated with primary pulmonary ALK-negative anaplastic large cell lymphoma. 61
31705818 2020
6
ALK-negative anaplastic large cell lymphoma with "Hodgkin-like" cytomorphology and nuclear expression of PAX5. 61
31784094 2020
7
"Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative. 61
32106310 2020
8
Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma. 61
32064308 2020
9
LncRNA MIR503HG Inhibits Non-Small Cell Lung Cancer Cell Proliferation by Inducing Cell Cycle Arrest Through the Downregulation of Cyclin D1. 61
32184667 2020
10
Aggressive Disease Course of Multiple Myeloma with Concomitant ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report with an Unusual Presentation. 61
32509362 2020
11
Follicular Dendritic Cell Sarcoma With Co-Expression of CD4 and CD30 Mimics Anaplastic Large Cell Lymphoma. 61
32547956 2020
12
Leukemic phase of ALK-negative anaplastic large cell lymphoma in a patient who is on androgenic steroids: A case report. 61
31871676 2020
13
[Detection of chromosomal translocations of DUSP22 and TP63 in ALK-negative anaplastic large cell lymphoma by fluorescence in situ hybridization and related clinical relevance]. 61
31594044 2019
14
DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. 61
31570354 2019
15
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. 61
30873584 2019
16
Pediatric mediastinal ALK- negative anaplastic large cell lymphoma (Hodgkin-like pattern) in a 13-year-old girl: a case report and review of literature. 61
31772744 2019
17
Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. 61
31278738 2019
18
Primary ALK-negative anaplastic large cell lymphoma with extensive bone involvement mimicking multiple myeloma and metastatic carcinoma. 61
31093934 2019
19
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. 61
31101622 2019
20
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. 61
30829413 2019
21
ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. 61
30685783 2019
22
A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT. 61
30562196 2019
23
Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. 61
30407628 2019
24
[Clinicopathological characteristics of adult T cell leukemia/lymphoma]. 61
30641639 2019
25
Granulysin, a novel marker for extranodal NK/T cell lymphoma, nasal type. 61
30151671 2018
26
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype. 61
29898383 2018
27
Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases. 61
29449683 2018
28
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. 61
29758012 2018
29
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. 61
29359238 2018
30
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. 61
29026208 2018
31
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as Disseminated Intravascular Coagulation and Hemophagocytic Lymphohistiocytosis: A Potentially Fatal Presentation. 61
29850298 2018
32
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. 61
28370436 2017
33
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. 61
28381153 2017
34
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. 61
29100307 2017
35
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. 61
28522440 2017
36
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. 61
28344319 2017
37
Indolent ALK-negative anaplastic large-cell lymphoma, DUSP22 rearranged, with an unusual immunophenotype in a human immunodeficiency virus patient. 61
28042680 2017
38
PAX-5 Positivity in Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma: A Case Report and Review of Literature. 61
28013563 2017
39
Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature. 61
27480544 2017
40
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. 61
28139895 2017
41
[Primary ALK-negative anaplastic large cell lymphoma of breast: report of a case]. 61
28072980 2017
42
[Granulomatous slack skin associated with ALK-negative anaplastic large cell lymphoma]. 61
28056306 2016
43
Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation. 61
28003232 2016
44
Cyclin D1 expression in peripheral T-cell lymphomas. 61
27469326 2016
45
[Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas]. 61
27995879 2016
46
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. 61
27460479 2016
47
[Outcome of haploidentical hematopoietic stem cell transplantation for non-Hodgkin lymphoma]. 61
27587245 2016
48
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. 61
27209536 2016
49
Cytological Diagnosis of Bilateral Breast Implant-Associated Lymphoma of the ALK-Negative Anaplastic Large-Cell Type. Clinical Implications of Peri-Implant Breast Seroma Cytological Reporting. 61
27079579 2016
50
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. 61
27263791 2016
Sources

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

About this section
Sources

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

About this section
Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.
Sources

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.79 STAT3 PMAIP1 MYC CXCR3 CCR4 BCL2L1
2
PEDF Induced Signaling 63
Show member pathways
 13.64 STAT3 MYC CXCR3 CCR4 BCL2L1 BCL2
3
Human cytomegalovirus infection 36
Show member pathways
 12.9 STAT3 MYC CCR4 BCL2L1 BCL2 BAX
4
Endometrial cancer 36
Show member pathways
 12.82 STAT3 PMAIP1 MYC BCL2L1 BCL2 BAX
5
Measles 36
Show member pathways
 12.78 STAT3 MYC BCL2L1 BCL2 BAX
6
Apoptotic execution phase 65
Show member pathways
 12.73 TP63 PMAIP1 BCL2L1 BCL2 BAX
7
ErbB signaling pathway 36 1
Show member pathways
 12.59 STAT3 MYC BCL2L1 BCL2 BAX
8
Pathways in cancer 36
12.59 STAT3 PMAIP1 MYC BCL2L1 BCL2 BAX
9
Immune response IL-23 signaling pathway 22
Show member pathways
 12.56 STAT3 MYC BCL2L1 BCL2 BAX
10
Apoptosis Modulation and Signaling 1
Show member pathways
 12.56 TP63 PMAIP1 MYC BCL2L1 BCL2 BAX
11
Th17 cell differentiation 36
Show member pathways
 12.55 STAT3 MYC BCL2L1 BCL2
12
Development Dopamine D2 receptor transactivation of EGFR 22
Show member pathways
 12.53 STAT3 BCL2L1 BCL2 BAX
13
MicroRNAs in cancer 36
12.5 TP63 STAT3 MYC BCL2
14
Prolactin Signaling Pathway 36 1
Show member pathways
 12.43 STAT3 MYC BCL2L1 BCL2 BAX
15
JAK-STAT signaling pathway 36
Show member pathways
 12.41 STAT3 MYC BCL2L1 BCL2
16
Development IGF-1 receptor signaling 22
Show member pathways
 12.36 STAT3 MYC BCL2L1 BAX
17
Viral carcinogenesis 36
12.28 STAT3 PMAIP1 CCR4 BAX
18
DNA Damage Response 1
Show member pathways
 12.28 PMAIP1 MYC BCL2L1 BCL2 BAX
19
MAPK Signaling: Mitogens 64
Show member pathways
 12.19 MYC BCL2L1 BCL2 BAX
20
Colorectal Cancer Metastasis 63
12.17 STAT3 MYC BCL2L1 BAX
21
Direct p53 effectors 1
12.03 TP63 PMAIP1 BCL2 BAX
22
Apoptosis and Autophagy 4
12.03 PMAIP1 MYC BCL2L1 BCL2 BAX
23
DNA Damage Response (only ATM dependent) 1
11.94 PMAIP1 MYC BCL2 BAX
24
Interleukin-4 and 13 signaling 65
11.93 STAT3 MYC BCL2L1 BCL2
25
TP53 Regulates Transcription of Cell Death Genes 65
Show member pathways
 11.9 TP63 PMAIP1 BAX
26
AGE-RAGE signaling pathway in diabetic complications 36
11.87 STAT3 BCL2 BAX
27
Amyotrophic lateral sclerosis (ALS) 36 1
11.85 BCL2L1 BCL2 BAX
28
Development EPO-induced Jak-STAT pathway 22
Show member pathways
 11.82 STAT3 MYC BCL2L1 BCL2
29
IL-6 signaling pathway 1
Show member pathways
 11.8 STAT3 MYC BCL2L1
30
Validated targets of C-MYC transcriptional activation 1
11.77 PMAIP1 MYC BAX
31
Small cell lung cancer 36
11.76 MYC BCL2L1 BCL2 BAX
32
C-MYB transcription factor network 1
11.75 MYC BCL2 ADA
33
Nanomaterial induced apoptosis 1
Show member pathways
 11.7 PMAIP1 BCL2L1 BCL2 BAX
34
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.67 MYC BCL2L1 BCL2
35
Activation of BH3-only proteins 65
Show member pathways
 11.65 TP63 PMAIP1 BCL2L1 BCL2 BAX
36
Platinum drug resistance 36
11.6 PMAIP1 BCL2L1 BCL2 BAX
37
Photodynamic therapy-induced AP-1 survival signaling. 1
11.54 BCL2L1 BCL2 BAX
38
Hepatitis C and Hepatocellular Carcinoma 1
11.54 STAT3 MYC BCL2L1
39
Integrated Cancer Pathway 1
11.49 MYC BCL2 BAX
40
IL-7 Signaling Pathway 1
Show member pathways
 11.46 STAT3 MYC BCL2L1
41
Ceramide signaling pathway 1
11.46 MYC BCL2 BAX
42
Photodynamic therapy-induced HIF-1 survival signaling 1
11.36 PMAIP1 BCL2L1 BAX
43
IL-10 Pathway 63
11.33 STAT3 MYC BCL2L1
44
14-3-3 and Regulation of BAD Activity 63
11.28 BCL2L1 BCL2 BAX
45
Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins 22
Show member pathways
 11.26 PMAIP1 BCL2L1 BCL2 BAX
46
Busulfan Pathway, Pharmacodynamics 60
Show member pathways
 11.2 STAT3 MYC BCL2L1 BCL2
47
Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2 22
11.18 MYC BCL2 BAX
48
Pathogenesis of ALS 63
11.12 BCL2L1 BCL2 BAX
49
Gemtuzumab ozogamicin Pathway, Pharmacokinetics/Pharmacodynamics 60
11.06 BCL2L1 BCL2 BAX
50
Overview of nanoparticle effects 1
10.99 BCL2 BAX
Sources

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

About this section

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.8 TP63 STAT3 PMAIP1 MYC BCL2L1 BCL2
2 pore complex GO:0046930 9.16 BCL2 BAX
3 Bcl-2 family protein complex GO:0097136 8.96 BCL2L1 BAX
4 mitochondrial outer membrane GO:0005741 8.92 PMAIP1 BCL2L1 BCL2 BAX

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.1 TP63 STAT3 MYC MSC FRK DUSP22
2 apoptotic process GO:0006915 10.06 TP63 PMAIP1 CXCR3 BCL2L1 BCL2 BAX
3 positive regulation of cell proliferation GO:0008284 10.03 STAT3 MYC DPP4 BCL2L1 BCL2
4 negative regulation of cell proliferation GO:0008285 10.02 STAT3 FRK BCL2 BAX ADARB1
5 response to drug GO:0042493 9.96 STAT3 MYC BCL2 ADA
6 cytokine-mediated signaling pathway GO:0019221 9.96 STAT3 MYC BCL2L1 BCL2
7 regulation of cell proliferation GO:0042127 9.92 STAT3 FRK DUSP22 ALK
8 defense response to virus GO:0051607 9.9 PMAIP1 BCL2L1 BCL2 ADARB1
9 regulation of cell cycle GO:0051726 9.88 STAT3 BCL2 BAX ADARB1
10 regulation of apoptotic process GO:0042981 9.85 TP63 PMAIP1 BCL2L1 BCL2 BAX ALK
11 male gonad development GO:0008584 9.83 BCL2L1 BCL2 BAX
12 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 BCL2L1 BCL2 BAX
13 response to radiation GO:0009314 9.74 CCR4 BCL2L1 BCL2
14 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.73 BCL2L1 BCL2 BAX
15 response to cytokine GO:0034097 9.73 STAT3 CD274 BCL2L1 BCL2
16 regulation of mitochondrial membrane potential GO:0051881 9.71 BCL2L1 BCL2 BAX
17 ovarian follicle development GO:0001541 9.71 MYC BCL2L1 BCL2 BAX
18 response to gamma radiation GO:0010332 9.7 MYC BCL2 BAX
19 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.67 BCL2 BAX
20 positive regulation of ATP biosynthetic process GO:2001171 9.65 STAT3 MYC
21 negative regulation of mitochondrial membrane potential GO:0010917 9.65 PMAIP1 BAX
22 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.65 TP63 PMAIP1 BCL2
23 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.64 TP63 BAX
24 hypothalamus development GO:0021854 9.64 MYC BAX
25 apoptotic mitochondrial changes GO:0008637 9.63 BCL2L1 BCL2 BAX
26 neuron apoptotic process GO:0051402 9.62 TP63 BCL2L1 BCL2 BAX
27 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0001844 9.61 PMAIP1 BAX
28 leukocyte homeostasis GO:0001776 9.61 BCL2 BAX
29 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.56 PMAIP1 BCL2L1 BCL2 BAX
30 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.55 DPP4 ADA
31 positive regulation of developmental pigmentation GO:0048087 9.51 BCL2 BAX
32 regulation of nitrogen utilization GO:0006808 9.49 BCL2 BAX
33 release of cytochrome c from mitochondria GO:0001836 9.46 PMAIP1 BCL2L1 BCL2 BAX
34 cell proliferation GO:0008283 9.43 TP63 STAT3 MYC BCL2L1 BCL2 BAX
35 regulation of mitochondrial membrane permeability GO:0046902 8.92 STAT3 PMAIP1 BCL2L1 BCL2

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.65 STAT3 DPP4 BCL2L1 BCL2 BAX
2 identical protein binding GO:0042802 9.56 TP63 STAT3 DPP4 CXCR3 BCL2L1 BCL2
3 adenosine deaminase activity GO:0004000 9.16 ADARB1 ADA
4 BH3 domain binding GO:0051434 8.8 BCL2L1 BCL2 BAX
Sources

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....